Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]
Awaiting development
Reference number: GID-TA11876
Expected publication date: TBC
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early December 2026. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.